Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
- 4 April 2005
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 20 (8), 937-944
- https://doi.org/10.1002/mds.20468
Abstract
The purpose of this study is to evaluate the real‐world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty‐one percent of patients fell into the Dysport‐to‐BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport‐to‐BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose‐conversion factors are not applicable. © 2005 Movement Disorder SocietyKeywords
This publication has 10 references indexed in Scilit:
- Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type AJournal of Biological Chemistry, 2003
- Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safetyToxicon, 2002
- A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in miceToxicon, 2001
- A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Costs of Treating Dystonias and Hemifacial Spasm with Botulinum Toxin APharmacoEconomics, 1997
- DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1Movement Disorders, 1997
- Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasmAlbrecht von Graefes Archiv für Ophthalmologie, 1997
- Therapeutic botulinum type a toxin: Factors affecting potencyToxicon, 1996
- Dose standardisation of botulinum toxin.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Effect of treatment with botulinum toxin on neurogenic blepharospasm.BMJ, 1985